244 related articles for article (PubMed ID: 32214378)
1. Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer.
Martino G; Catalano A; Agostino RM; Bellone F; Morabito N; Lasco CG; Vicario CM; Schwarz P; Feldt-Rasmussen U
PLoS One; 2020; 15(3):e0230681. PubMed ID: 32214378
[TBL] [Abstract][Full Text] [Related]
2. Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters.
Borreani C; Alfieri S; Infante G; Miceli R; Mariani P; Bosisio M; Vernieri C; Bianchi GV; Capri G
Oncology; 2021; 99(2):84-95. PubMed ID: 32992318
[TBL] [Abstract][Full Text] [Related]
3. Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy.
Pedersini R; Amoroso V; Maffezzoni F; Gallo F; Turla A; Monteverdi S; Ardine M; Ravanelli M; Vassalli L; Rodella F; Formenti AM; Dalla Volta A; Simoncini EL; Giustina A; Maroldi R; Berruti A
JAMA Netw Open; 2019 Sep; 2(9):e1911080. PubMed ID: 31560383
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life of postmenopausal Chinese women with hormone receptor-positive early breast cancer during treatment with adjuvant aromatase inhibitors: a prospective, multicenter, non-interventional study.
Cao A; Zhang J; Liu X; Wu W; Liu Y; Fan Z; Zhang A; Zhou T; Fu P; Wang S; Ouyang Q; Tang J; Jiang H; Zhang X; Pang D; He J; Shi L; Wang X; Sheng Y; Mao D; Shao Z
Health Qual Life Outcomes; 2016 Mar; 14():51. PubMed ID: 27009092
[TBL] [Abstract][Full Text] [Related]
5. Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors.
Catalano A; Gaudio A; Agostino RM; Morabito N; Bellone F; Lasco A
J Endocrinol Invest; 2019 Nov; 42(11):1337-1343. PubMed ID: 31127591
[TBL] [Abstract][Full Text] [Related]
6. Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis.
Taichman LS; Van Poznak CH; Inglehart MR
Support Care Cancer; 2016 Nov; 24(11):4815-24. PubMed ID: 27455851
[TBL] [Abstract][Full Text] [Related]
7. Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
Dibble KE; Bellizzi KM; Taxel P; Pescatello LS; Siembida EJ; Schifano ED; Guarneri S; Tannenbaum S
Support Care Cancer; 2021 May; 29(5):2385-2394. PubMed ID: 32918610
[TBL] [Abstract][Full Text] [Related]
8. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
10. Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer.
Villa P; Lassandro AP; Amar ID; Vacca L; Moruzzi MC; Ferrandina G; Terribile D; Masetti R; Scambia G
Menopause; 2016 Jan; 23(1):33-9. PubMed ID: 26308233
[TBL] [Abstract][Full Text] [Related]
11. Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study.
Galantino ML; Callens ML; Cardena GJ; Piela NL; Mao JJ
Altern Ther Health Med; 2013; 19(6):38-44. PubMed ID: 24254037
[TBL] [Abstract][Full Text] [Related]
12. Serum apelin levels and body composition changes in breast cancer patients treated with an aromatase inhibitor.
Salman T; Demir L; Varol U; Akyol M; Oflazoglu U; Yildiz Y; Taskaynatan H; Cengiz H; Guvendi G; Kucukzeybek Y; Alacacioglu A; Tarhan O
J BUON; 2016; 21(6):1419-1424. PubMed ID: 28039702
[TBL] [Abstract][Full Text] [Related]
13. Comparing exercise responses to aerobic plus resistance training between postmenopausal breast cancer survivors undergoing aromatase inhibitor therapy and healthy women.
de Paulo TRS; Winters-Stone KM; Viezel J; Rossi FE; Aro BL; Trindade ACAC; Codogno JS; Freitas Junior IF
Disabil Rehabil; 2019 Sep; 41(18):2175-2182. PubMed ID: 29644889
[No Abstract] [Full Text] [Related]
14. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
15. Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors.
Catalano A; Morabito N; Agostino RM; Basile G; Gaudio A; Atteritano M; Natale G; Xourafa A; Morini E; Adamo V; Lasco A
Menopause; 2017 Jan; 24(1):85-91. PubMed ID: 27575547
[TBL] [Abstract][Full Text] [Related]
16. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
[TBL] [Abstract][Full Text] [Related]
17. [A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Sun J; Wang Q; Wang L; Gui L; Li Q; Luo Y; Zhang S; Zhang P
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):403-407. PubMed ID: 32482030
[No Abstract] [Full Text] [Related]
18. Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on depression, anxiety, functional capacity and health-related quality of Life in breast cancer survivors during adjuvant endocrine therapy.
Custódio IDD; Nunes FSM; Lima MTM; de Carvalho KP; Alves DS; Chiaretto JF; Canto PPL; Paiva CE; de Paiva Maia YC
BMC Cancer; 2022 Aug; 22(1):860. PubMed ID: 35933326
[TBL] [Abstract][Full Text] [Related]
19. Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey.
Smedsland SK; Vandraas KF; Bøhn SK; Dahl AA; Kiserud CE; Brekke M; Falk RS; Reinertsen KV
Breast Cancer Res Treat; 2022 May; 193(1):139-149. PubMed ID: 35226237
[TBL] [Abstract][Full Text] [Related]
20. Quantitative ultrasound and DXA measurements in aromatase inhibitor-treated breast cancer women receiving denosumab.
Catalano A; Gaudio A; Morabito N; Basile G; Agostino RM; Xourafa A; Atteritano M; Morini E; Natale G; Lasco A
J Endocrinol Invest; 2017 Aug; 40(8):851-857. PubMed ID: 28332172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
